Skip to main content
82 search results for:

Durvalumab 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 17-11-2022 | FDA | News | Article
    approvalsWatch

    FDA approves durvalumab, tremelimumab, chemo triplet for metastatic NSCLC

    medwireNews : The US FDA has authorized  the use of durvalumab plus tremelimumab alongside first-line platinum-based chemotherapy in the metastatic non-small-cell lung cancer (NSCLC) setting.

  2. 10-09-2022 | ESMO 2022 | Conference coverage | Article

    No clinical benefit of adding oleclumab to durvalumab–chemo in advanced TNBC

    Adding the CD73 inhibitor oleclumab to durvalumab plus platinum-doublet chemotherapy does not improve the clinical benefit rate among women with treatment-naïve advanced triple-negative breast cancer, the SYNERGY investigators have found.

  3. 11-05-2022 | Small-cell lung cancer | News | Article

    Durvalumab–CRT potential for limited-stage SCLC demonstrated

    Individuals with limited-stage small-cell lung cancer could benefit from the addition of durvalumab to chemoradiotherapy, suggest early data.

  4. 05-05-2022 | ESMO Breast 2022 | Conference coverage | Article

    Datopotamab deruxtecan–durvalumab combo shows promise for advanced TNBC

    Early results from the BEGONIA trial point to the potential of first-line treatment with datopotamab deruxtecan plus durvalumab in people with advanced triple-negative breast cancer.

  5. 19-02-2022 | ASCO GU 2022 | Conference coverage | Article

    BAYOU hints at potential of durvalumab–olaparib in mutated metastatic UC

    Adding olaparib to durvalumab did not improve progression-free survival in the overall BAYOU trial population comprising unselected patients with metastatic urothelial carcinoma, but there was a signal of efficacy in the subgroup with homologous recombination repair gene mutations, say investigators. This independent news story was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

  6. 26-01-2022 | Non-small-cell lung cancer | News | Article

    Radiotherapy futile add-on to durvalumab–tremelimumab in refractory NSCLC

    Adding low-dose or hypofractionated radiotherapy to durvalumab plus tremelimumab offers no significant benefit to people with non-small-cell lung cancer that is resistant to PD-1 or PD-L1 inhibition, US study findings indicate.

  7. 03-11-2021 | Small-cell lung cancer | Adis Journal Club | Article
    Targeted Oncology

    Durvalumab: A Review in Extensive-Stage SCLC

    Durvalumab: clinical considerations in ES-SCLC

    The efficacy of durvalumab was also sustained with longer follow-up.

  8. 22-09-2021 | ESMO 2021 | Conference coverage | Article
    News in brief

    CASPIAN update cements durvalumab–chemo as standard of care for extensive-stage SCLC

    The overall survival advantage offered by the use of durvalumab alongside first-line chemotherapy in people with extensive-stage small-cell lung cancer is sustained over time, suggests the 3-year follow-up of the CASPIAN study.

  9. 18-09-2021 | ESMO 2021 | Conference coverage | Article

    COAST points to potential of durvalumab combinations in stage III NSCLC

    Individuals with unresectable locally advanced non-small-cell lung cancer and no progression after chemoradiotherapy could benefit from the addition of the CD73 inhibitor oleclumab or the NKG2A-targeted agent monalizumab to consolidation durvalumab, suggest phase 2 results.

  10. 09-09-2021 | WCLC 2021 | Conference coverage | Article

    Durvalumab–tremelimumab plus chemo ‘a potential new first-line option’ for metastatic NSCLC

    The addition of durvalumab plus tremelimumab to chemotherapy significantly improves the outcomes of people with untreated metastatic non-small-cell lung cancer, shows the POSEIDON trial.

  11. 19-07-2021 | Non-small-cell lung cancer | News | Article

    Perioperative durvalumab addition promising for stage IIIA NSCLC

    Adding perioperative durvalumab to neoadjuvant chemotherapy could be a feasible option for patients with resectable, locally advanced non-small-cell lung cancer with mediastinal lymph node involvement, suggest phase 2 trial data.

  12. 25-06-2021 | Non-small-cell lung cancer | News | Article

    Adding SBRT to neoadjuvant durvalumab shows promise in early NSCLC

    The addition of stereotactic body radiotherapy to neoadjuvant durvalumab significantly improves the major pathologic response rate in patients with early-stage non-small-cell lung cancer, phase 2 trial data suggest.

  13. 10-06-2021 | ASCO 2021 | Conference coverage | Article

    Long-term benefits to neoadjuvant durvalumab in triple-negative breast cancer

    Adding the PD-L1 inhibitor durvalumab to neoadjuvant chemotherapy may improve survival outcomes in people with triple-negative breast cancer, show GeparNUEVO data presented at the 2021 ASCO Annual Meeting.

  14. 06-06-2021 | ASCO 2021 | Conference coverage | Article
    News in brief

    PACIFIC at 5 years shows ‘robust and sustained’ OS benefit with durvalumab

    Five-year findings from the PACIFIC trial for patients with unresectable stage III non-small-cell lung cancer continue to show survival benefits with 1 year of durvalumab therapy versus placebo after platinum-based chemoradiotherapy.

  15. 20-04-2021 | Mesothelioma | News | Article

    Retreatment with tremelimumab–durvalumab feasible in mesothelioma patients

    The NIBIT-MESO-1 trial suggests that retreatment with tremelimumab plus durvalumab could be a viable option for patients with unresectable mesothelioma who progress after initially benefiting from the combination.

  16. 13-02-2021 | ASCO GU 2021 | Conference coverage | Article

    Perioperative durvalumab feasible for muscle-invasive urothelial carcinoma

    Early data from the SAKK 06/17 trial point to the feasibility of incorporating durvalumab into the perioperative treatment regimen of patients with resectable muscle-invasive urothelial carcinoma.

  17. play
    19-09-2020 | ESMO 2020 | Conference coverage | Video

    DANUBE: Durvalumab misses the mark in advanced urothelial cancer

    Thomas Powles outlines the DANUBE trial pitting durvalumab, with or without tremelimumab, against chemotherapy in the metastatic urothelial cancer setting. This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

  18. 08-10-2020 | ESMO 2020 | Conference coverage | Article

    Durvalumab, alone or with tremelimumab, fails to boost metastatic UC survival

    The DANUBE trial has ruled out the first-line use of durvalumab monotherapy or alongside tremelimumab in patients with metastatic urothelial carcinoma after failing to show an overall survival advantage for either option relative to standard of care chemotherapy.

  19. 03-08-2020 | EMA | News | Article
    approvalsWatch

    EMA recommends new indication for durvalumab

    medwireNews : The EMA’s Committee for Medicinal Products for Human Use has adopted an extension to the indication for durvalumab to include patients with extensive-stage small-cell lung cancer.

  20. 25-09-2020 | ESMO 2020 | Conference coverage | Article

    Long-term ES-SCLC outcomes on durvalumab–chemotherapy predicted by PFS duration

    A progression-free survival of at least 12 months is a strong indicator of good survival outcomes at 2 years in patients with extensive-stage small-cell lung cancer taking durvalumab alongside first-line platinum–etoposide, even in those with poor prognostic factors, analysis of CASPIAN data shows.

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.